DNA and purine metabolism enzymes

DNA and purine metabolism enzymes encompass a diverse group of proteins responsible for the de novo synthesis, salvage, and catabolism of purine nucleotides, which are essential building blocks for DNA and RNA (StatPearls: Purine Metabolism, 2023). Key enzymes in this category include dihydrofolate reductase (DHFR), inosine monophosphate dehydrogenase (IMPDH), ribonucleotide reductase (RNR), and xanthine oxidase (XO). These enzymes are critical for cellular proliferation, as they maintain the balanced pools of dNTPs required for high-fidelity DNA replication (Nature Reviews Cancer, 2013). In clinical practice, these enzymes are major therapeutic targets across multiple therapeutic areas. For instance, DHFR is inhibited by methotrexate to treat cancer and autoimmune diseases, while XO is targeted by allopurinol to manage gout by reducing uric acid production. Because these pathways are fundamental to all dividing cells, drugs targeting them (antimetabolites) often exhibit a narrow therapeutic index. This frequently results in systemic side effects such as myelosuppression and gastrointestinal toxicity (NCBI: Nucleotide Metabolism, 2021). Additionally, genetic variations in enzymes like thiopurine S-methyltransferase (TPMT) can significantly impact the metabolism and safety of drugs like 6-mercaptopurine, necessitating biomarker-based patient screening.

Other names

Purine biosynthetic enzymesNucleotide metabolism enzymesPurine salvage and de novo pathway enzymesPurine metabolism enzymes

Drugs targeting these enzymes typically act as antimetabolites that competitively inhibit enzyme activity by mimicking natural purine substrates or cofactors, such as folic acid. This inhibition leads to the depletion of essential nucleotide pools, the inhibition of DNA polymerase-mediated synthesis, or the incorporation of fraudulent nucleotides into the DNA strand, which ultimately triggers cell cycle arrest or apoptosis (Nature Reviews Cancer, 2013).